Late gadolinium enhancement identified with cardiacmagnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death

European Heart Journal Cardiovascular Imaging

Volumn 16, Issue 6, 2015, Pages 634-641

  Nadel, James ^a   Lancefield, Terase ^b   Voskoboinik, Aleksandr ^b   Taylor, Andrew J ^b  

^a UNIVERSITY OF NOTRE DAME   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Arrhythmia; Defibrillation; Late gadolinium enhancement; Magnetic resonance imaging; Sarcoidosis; Sudden cardiac death

Indexed keywords

CORTICOSTEROID; GADOLINIUM; IMMUNOSUPPRESSIVE AGENT; CONTRAST MEDIUM;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONTRAST ENHANCEMENT; FEMALE; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PACEMAKER; PRIORITY JOURNAL; SARCOIDOSIS; SUDDEN CARDIAC DEATH; SURVIVAL RATE; CARDIOMYOPATHY; COMPLICATION; DEATH, SUDDEN, CARDIAC; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TACHYCARDIA, VENTRICULAR;

CARDIOMYOPATHIES; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOIDOSIS; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR;

EID: 84942116494     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jeu294     Document Type: Article

References (36)

1. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 1977;63:86-108.
2. Smith G, Brownell I, Sanchez M, Prystowsky S. Advances in the genetics of sarcoidosis. Clin Genet 2008;73:401-12.
3. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis.NEngl J Med 2007;357:2153-65.
4. Gillman A, Steinfort C. Sarcoidosis in Australia. Intern Med J 2007;37:356-9.
5. Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol 2009;104:571-7.
6. Silverman K, Hutchins G, Bulkley B. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.
7. Tadamura E, Yamamuro M, Kubo S, Kanao S, Saga T, HaradaMet al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. Am J Roentgenol 2005;185:110-5.
8. MatsuiY, Iwai K, TachibanaT, FruieT, Shigematsu N, IzumiTet al. Clinicopathological study on fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976;278:455-69.
9. Sekhri V, Sanal S, DeLorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci 2011;7:546-54.
10. Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN et al. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.
11. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart 2006;92:282-8.
12. Uemura A, Morimoto S-I, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999; 138:299-302.
13. Matsuki M, Matsuo M.MRfindings of myocardial sarcoidosis. Clin Radiol 2000;55:323.
14. Vignaux O, Dhote R, Duboc D, Blanche P, Devaux J-Y, Weber S et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 2002;26:762-7.
15. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110: 520-7.
16. Smedema J-P, Snoep G, van Kroonenburgh MP, van Geuns R-J, Dassen WR, Gorgels AP et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45: 1683-90.
17. Smedema J-P, Snoep G, van Kroonenburgh MP, van Geuns R-J, Cheriex EC, Gorgels AP et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005;128:1629-37.
18. Yazaki Y, Isobe M, Hiroe M, Morimoto S-I, Hiramitsu S, Nakano T et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.
19. Grutters J, van Den Bosch J. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006;28:627-36.
20. Winters SL, Cohen M, Greenberg S, Stein B, Curwin J, Pe E et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. JAmColl Cardiol 1991;18:937-43.
21. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336-46.
22. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythmabnormalities. J Cardiovasc Electrophysiol 2009;20:578-83.
23. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NM, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythmabnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51: e1-e62.
24. Zacek P, Omran N, Chek JL, Krbal L, Vojacek J, Harrer J. Cardiac sarcoidosis. J Card Surg 2013;28:525-8.
25. Paz HL, McCormick DJ, Kutalek SP, Patchefsky A. The automated implantable cardiac defibrillator prophylaxis in cardiac sarcoidosis. Chest 1994;106:1603-7.
26. Sharma OP. Diagnosis of cardiac sarcoidosis an imperfect science, a hesitant art. Chest 2003;123:18-9.
27. Staub B, Biederman R. Predicting potentially fatal conductive disease in sarcoidosis: can cardiac MRI define the risk? J Am Coll Cardiol 2013;61(10-S). http://content.onlinejacc.org/article.aspx?articleid=1665605.
28. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.
29. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, JaroudiWA et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
30. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.
31. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:925-9.
32. Kron J, SauerW, Schuller J, Bogun F, Crawford T, Sarsam S et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013;15:347-54.
33. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002;122:1895-901.
34. Osborne M, Hulten E, Singh A, Waller A, Bittencourt M, StewartGet al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-74.
35. Chiu C-Z, Nakatani S, Zhang G, TachibanaT, Ohmori F, YamagishiMet al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-6.
36. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, GarciaFC et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.